In the context of regenerative medicine, therapy using autologous cells (in combination with platelet-rich plasma) appears to be a promising option. The so-called medicinal signaling cells (MSC), also known as mesenchymal stem cells, can be obtained, for example, from bone marrow, subcutaneous adipose tissue, or umbilical cord blood, and can be applied to targets of degeneration or inflammation.
Read More